title: [Efficacy of intravitreal bevacizumab for age-related macular degeneration].
abstract: OBJECTIVE
  To investigate the efficacy of intravitreal bevacizumab (IVB) for neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  We conducted a retrospective study of 29 eyes of 29 patients with AMD (19 eyes) and polypoidal choroidal vasculopathy (PCV; 10 eyes), who were followed up at least 1 year after the initial IVB (1.0 mg/0.04 ml). The eyes were classified according to the lesion type and size. Best-corrected visual acuity (BCVA) and central retinal thickness were examined before and 3 months, 6 months and 12 months after the IVB.
  
  
  RESULTS
  The mean application times of IVB were 2.1 in 1 year. When classifying the eyes according to the lesion type, BCVA improved in 5 (26.3%) eyes with AMD and 1 (10.0%) eye with PCV by over 0.2 logarithmic minimum angle of resolution (logMAR) units. The BCVA decreased significantly 1 year after the IVB in eyes with PCV (p = 0.032). When classifying the eyes according to the lesion size, BCVA improved by over 0.2 logMAR units in the 4 (50.0%) eyes with a size of less than 1 disc diameter, 1 (10.0%) eye with the size of 1 to 3 disc diameters, and 1 (9.1%) eye with the size of over 4 disc diameters. The BCVA decreased significantly 1 year after the IVB in the eyes with the size of 1 to 3 disc diameters and with the size of over 4 disc diameters (p = 0.028, 0.013, respectively). The central retinal thickness did not change significantly at any time point compared to that before the IVB.
  
  
  CONCLUSIONS
  These results suggest that IVB may be efficacious in preserving visual acuity in AMD eyes and in eyes with the size of less than 1 disc diameter.
authors.affiliation: Osaka Rosai Hospital Clinical Research Center for Optical Sensory Organ Disability, Japan.
authors.forename: Chikako
authors.initials: C
authors.lastname: Ueno
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Emi
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Sato
authors.forename: Takamasa
authors.initials: T
authors.lastname: Minami
authors.forename: Eriko
authors.initials: E
authors.lastname: Nakatani
authors.forename: Ryo
authors.initials: R
authors.lastname: Iseki
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Tanaka
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Oura
authors.forename: Kosaku
authors.initials: K
authors.lastname: Sawada
authors.forename: Takeshi
authors.initials: T
authors.lastname: Soma
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Morita
authors.forename: Shigeru
authors.initials: S
authors.lastname: Sato
authors.forename: Hajime
authors.initials: H
authors.lastname: Bando
authors.forename: Toshihide
authors.initials: T
authors.lastname: Ikeda
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D012189:Retrospective Studies; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab